Results 221 to 230 of about 42,703 (308)

Faculty Opinions recommendation of Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.

, 2013
Direk Limmathurotsakul, Cherry Lim
openalex   +2 more sources

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pharmacol
Xiong W, Li Y, Hu L, He G, Huang J.
europepmc   +1 more source

Complications of invasive oral procedures in patients with immune-mediated inflammatory disorders treated with biological and conventional disease-modifying antirheumatic drugs or glucocorticoids: a scoping review of the literature. [PDF]

BMC Oral Health
Radoi L, Kadri M, Gosset M.
europepmc   +1 more source

Trends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022. [PDF]

Arthritis Rheumatol
Yalamanchili P, Lee LY, Bushnell G, Mannion ML, Dave CV, Horton DB.   +5 more
europepmc   +1 more source

Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry". [PDF]

Rheumatol Ther
Liu Z, Tian M, Duan L.
europepmc   +1 more source

Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register [PDF]

, 2018
Chipping, Jacqueline R, Gwinnutt, James M, Lunt, Mark, MacGregor, Alexander J, Marshall, Tarnya, Symmons, Deborah P M, Verstappen, Suzanne M M   +6 more
core   +1 more source

Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis. [PDF]

Clin Rheumatol
Künzler T, Bamert M, Sprott H.
europepmc   +1 more source

Influencers of Achievement of Remission and Low Disease Activity in Response to Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis. [PDF]

Cureus
Oyoo GO, Guantai A, Moots RJ, Okalebo F, Osanjo GO.   +4 more
europepmc   +1 more source

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.

JAMA Netw Open
Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N.   +14 more
europepmc   +1 more source

Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. [PDF]

Clin Rheumatol
Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, Giordano SH.   +6 more
europepmc   +1 more source